Taysha Gene Therapies (NASDAQ:TSHA) Receives “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report issued on Thursday,Weiss Ratings reports.

A number of other analysts also recently commented on the company. Robert W. Baird increased their price target on Taysha Gene Therapies from $7.00 to $12.00 and gave the company an “outperform” rating in a research report on Thursday, October 2nd. Raymond James Financial began coverage on Taysha Gene Therapies in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $13.00 price objective for the company. Bank of America began coverage on Taysha Gene Therapies in a report on Friday, July 11th. They set a “buy” rating and a $8.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and set a $10.00 price objective on shares of Taysha Gene Therapies in a report on Friday, October 17th. Finally, Wells Fargo & Company increased their price objective on Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.67.

Taysha Gene Therapies Stock Performance

Shares of TSHA opened at $4.91 on Thursday. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -14.44 and a beta of 0.99. The stock has a 50 day moving average of $3.84 and a 200 day moving average of $2.94. Taysha Gene Therapies has a 12 month low of $1.05 and a 12 month high of $5.51.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). The business had revenue of $1.99 million for the quarter, compared to analysts’ expectations of $1.61 million. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. As a group, sell-side analysts forecast that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total value of $646,000.00. Following the completion of the transaction, the insider directly owned 1,006,439 shares of the company’s stock, valued at $3,250,797.97. This trade represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.78% of the stock is owned by insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of large investors have recently made changes to their positions in the stock. Octagon Capital Advisors LP boosted its holdings in shares of Taysha Gene Therapies by 17.7% in the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after acquiring an additional 1,892,500 shares during the period. Jefferies Financial Group Inc. boosted its holdings in shares of Taysha Gene Therapies by 4,105.3% in the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock worth $23,825,000 after acquiring an additional 10,068,479 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in shares of Taysha Gene Therapies in the second quarter worth $11,178,000. Tybourne Capital Management HK Ltd. boosted its holdings in shares of Taysha Gene Therapies by 10.7% in the second quarter. Tybourne Capital Management HK Ltd. now owns 4,095,000 shares of the company’s stock worth $9,459,000 after acquiring an additional 395,000 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Taysha Gene Therapies by 3.5% in the second quarter. Geode Capital Management LLC now owns 3,793,572 shares of the company’s stock worth $8,765,000 after acquiring an additional 128,840 shares during the period. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.